Desonide (desonide) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Desonide - Desonide lotion

    Get your patient on Desonide - Desonide lotion (Desonide)

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Desonide - Desonide lotion prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    Desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    Desonide lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition. SHAKE LOTION WELL BEFORE USING.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

    Desonide lotion should not be used with occlusive dressings.

    Contraindications

    CONTRAINDICATIONS

    Desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

    Adverse Reactions

    ADVERSE REACTIONS

    In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.

    The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.

    To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Description

    DESCRIPTION

    Desonide Lotion USP, 0.05% contain desonide, USP (Pregna-1,4-diene-3,20-dione,11,21- dihydroxy-16,17 [(1-methylethylidene) bis (oxy)]- (11β,16α)- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic agents.

    Chemically, desonide, USP is C 24 H 32 O 6 . It has the following structural formula:

    Referenced Image

    Desonide, USP has the molecular weight of 416.51. It is a white to almost white crystalline powder which is practically insoluble in water, sparingly soluble in ethanol and in acetone, soluble in chloroform.

    Each gram of desonide lotion USP, 0.05% contains 0.5 mg of desonide, USP in a base of cetyl alcohol, edetate disodium, glyceryl stearate SE, light mineral oil, methylparaben, propylene glycol, propylparaben, purified water, sodium lauryl sulfate, sorbitan monostearate, and stearyl alcohol. May contain citric acid and/or sodium hydroxide for pH adjustment.

    Pharmacology

    CLINICAL PHARMACOLOGY

    Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 .

    Pharmacokinetics

    The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressing with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

    Studies performed with desonide lotion indicate that they are in the low to medium range of potency as compared with other topical corticosteroids.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    Desonide Lotion USP, 0.05% is supplied in 59 mL and 118 mL bottles containing:

    2 fl oz (59 mL) NDC 62332-550-59

    4 fl oz (118 mL) NDC 62332-550-18

    Storage Conditions: Store between 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

    Manufactured for:

    Alembic Pharmaceuticals, Inc.

    Bedminster, NJ 07921, USA

    Manufactured by:

    Alembic Pharmaceuticals Limited

    (Derma Division),

    Karakhadi, Vadodara 391450, India.

    Mfg. License No.: G/25/2216

    Revised: 07/2025

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Desonide - Desonide lotion PubMed™ news

      Show the latest PubMed™ articles for Desonide - Desonide lotion